Left supraclavicular (Virchow’s) node metastasis detected before primary infradiaphragmatic tumor: a case series

Yumi Mochizuki1*, Maiko Tsuchiya2, Jun Oyama3, Akane Wada2, Takuma Kugimoto1, Takeshi Kuroshima1, Hideaki Hirai1, Hirofumi Tomioka1, Hiroyuki Harada1, Tohru Ikeda2 and Takumi Akashi4

Abstract

**Background:** Metastasis of infradiaphragmatic tumors to the left supraclavicular lymph node is reported to be rare. When metastasis is detected in the left supraclavicular node in patients with head and neck carcinoma, locating the primary cancer remains a difficult and time-consuming challenge despite the dramatic development of screening technologies and treatment methods.

**Case presentation:** We report three cases of malignant infradiaphragmatic tumor diagnosed following an initial finding of left supraclavicular node metastasis after surgery for tongue squamous cell carcinoma (follow-up period, range 18–62 months). In these cases, adenocarcinoma was diagnosed based on left supraclavicular node biopsies, and a second primary tumor was found, in a 78-year-old Japanese woman with a diagnosis of cholangiocarcinoma, a 64-year-old Japanese man with a diagnosis of bladder carcinoma, and a 61-year-old Japanese man with a diagnosis of prostate carcinoma. In the cholangiocarcinoma case, carbohydrate antigen 19-9 and alpha-fetoprotein levels helped to diagnose cholangiocarcinoma. Palliative care only was given, with survival for 11 months after diagnosis of lymph node metastasis. In the bladder carcinoma case, pathological analysis of fine-needle aspiration biopsy specimen of the metastatic cervical lymph node showed atypical cells with slight squamous differentiation. Hematoxylin–eosin staining of the bladder lesion did not identify a clear glandular or squamous component, and we could not make a definitive diagnosis of whether the lesion was poorly differentiated squamous cell carcinoma, adenocarcinoma, or high-grade urothelial carcinoma. GATA3 staining aided in the diagnosis of urothelial bladder cancer with left supraclavicular node metastasis. He survived for 2 months after diagnosis of left supraclavicular lymph node metastasis. In the prostate carcinoma case, 18F-fluorodeoxyglucose uptake was weak. Prostate-specific antigen levels and magnetic resonance imaging findings aided the diagnostic process. This patient underwent bilateral orchiectomy and adjuvant hormonal therapy and survived for 47 months after diagnosis of left supraclavicular node metastasis.

**Conclusions:** Pathological diagnosis on the basis of immunohistochemistry and specific diagnosis methods such as radiological and serological assessments are important for providing rapid diagnosis and appropriate treatment.

**Keywords:** Intrahepatic cholangiocarcinoma, Bladder carcinoma, Prostate carcinoma, Left supraclavicular (Virchow’s) node, Left supraclavicular node metastasis, Oral cancer

Introduction

Since Virchow’s time, the survival rates of cancer patients have improved because of dramatic research advances in the epidemiology of cancer and the development of screening technologies and treatment methods.
Supraclavicular lymph node metastasis has been reported to be more common in patients with lung and breast tumors (18.7% and 18.6%, respectively) [1, 2]. However, when metastasis is detected in the left supraclavicular node in patients with head and neck carcinoma, locating the primary cancer remains a difficult and time-consuming challenge. The accumulation of cases and the search for optimal therapeutic strategies remain important [2].

Patients with oral squamous cell carcinoma and those with other types of head and neck cancer are at higher risk of second primary cancer than patients with cancers at most other sites [3]. Mroueh et al. found a second primary cancer in 10% of patients with oral squamous cell carcinoma in their cohort [3], while Min et al. reported that the risk of a second primary oral cancer was higher (standardized incidence ratio 16.25, 95% confidence interval 13.04–20.02) than that of nonoral second primary cancer (standardized incidence ratio 1.37, 95% confidence interval 1.29–1.45) in Korean patients with cancer in the oral cavity [4]. In patients with tongue carcinoma, the second primary cancer most frequently occurs in the oropharynx, followed by the esophagus and larynx [3, 4]. In contrast, second primary cancer at other sites, such as the intrahepatic bile duct, bladder, and prostate, is rare in patients with tongue carcinoma.

Metastasis of infradiaphragmatic tumors to the left supraclavicular lymph node is also reported to be rare. The incidence of metastasis has been reported to be 3.6% for intrahepatic cholangiocarcinoma [1], 1.4% for bladder carcinoma [5], and approximately 0.3% for prostate carcinoma [6–8].

We encountered three patients with initial findings of left supraclavicular lymph node metastasis before detection of the primary infradiaphragmatic tumor during follow-up after surgery for tongue cancer. Here, we report these three cases and describe our diagnostic strategy.

Case series
Case 1
A 78-year-old Japanese woman with a diagnosis of tongue carcinoma underwent partial glossectomy in May 2002 and ipsilateral neck dissection (levels I–V) in July 2002. The pathological diagnosis was poorly differentiated squamous cell carcinoma (pT1N2bM0, according to the Union for International Cancer Control (UICC) TNM classification, 7th edition). She had no notable medical history at the time of her treatment for tongue carcinoma. We subsequently palpated left-sided supraclavicular lymphadenopathy at a postsurgical follow-up visit in July 2003 (Fig. 1A). Biopsy of the left supraclavicular lymph node yielded a diagnosis of adenocarcinoma (Fig. 2). Her carbohydrate antigen 19-9 (CA19-9) and alpha-fetoprotein levels were elevated to 4100 U/mL and 49.0 ng/dL, respectively. Infiltrative intrahepatic cholangiocarcinoma was detected on whole-body computed tomography (CT) scan (Fig. 1B). The patient consented to additional tissue biopsy of the bile duct, and the clinical diagnosis was cholangiocarcinoma (T2N1M1). She opted for palliative care and died 11 months after detection of left supraclavicular lymph node metastasis.

Case 2
A 64-year-old Japanese man underwent ipsilateral neck dissection (levels I–III), partial glossectomy, and forearm flap reconstruction for moderately differentiated squamous cell carcinoma of the tongue in February
2007. His medical history at the time when tongue carcinoma was detected included chronic otitis media. The pathological diagnosis was poorly differentiated squamous cell carcinoma (pT2N1M0). He revisited our department in March 2012 after noticing left supraclavicular lymphadenopathy (Fig. 3A). Fine-needle aspiration biopsy of the left supraclavicular lymph node revealed atypical cells with slight squamous differentiation, which was diagnosed as class IV, and biopsy of the left supraclavicular lymph node led to a diagnosis of carcinoma (Fig. 4A). Primary cancer screening was started in the head and neck and lung regions, but during that time, he developed postrenal renal failure (Fig. 3B), and a bladder tumor was found on an enhanced pelvic CT scan (Fig. 3C). Hematoxylin–eosin staining of the bladder lesion did not identify a clear glandular or squamous component, and we could not make a definitive diagnosis of whether the lesion was poorly differentiated squamous cell carcinoma, adenocarcinoma, or high-grade urothelial carcinoma (Fig. 4B). Immunopathological examination of the left supraclavicular lymph node showed CK7(+), CK20(−), and GATA3(+) (Fig. 5A), and the bladder lesion showed CK7(+), CK20(−), and GATA3(+) (Fig. 5B). On the other hand, immunopathological examination of the squamous cell carcinoma on the tongue showed GATA3(−) (Fig. 5C). Based on these pathological findings, the diagnosis was compatible with primary bladder cancer with metastasis to the left supraclavicular lymph node (pT2N2M1). The patient opted for palliative care and died 2 months later.
Case 3
A 61-year-old Japanese man underwent ipsilateral neck dissection (levels I–III), partial glossectomy, and forearm flap reconstruction for poorly differentiated squamous cell carcinoma on the right side of the tongue in March 2011. His medical history included hypertension and a duodenal ulcer. The pathological diagnosis was poorly differentiated squamous cell carcinoma (pT2N0M0). Follow-up $^{18}$F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography ($^{18}$F-FDG-PET/CT) in March 2013 showed intense $^{18}$F-FDG accumulation in the left supraclavicular (Fig. 6A) and right obturator (Fig. 6B) lymph nodes. $^{18}$F-FDG uptake in the prostate was weak (Fig. 6C). Biopsy of the left supraclavicular lymph node gave a diagnosis of adenocarcinoma (Fig. 7A). Contrast-enhanced magnetic resonance imaging (MRI) of the pelvis showed adenopathy of the obturator nodes on the right side of the prostate region and an enhancing lesion in the prostate on contrast-enhanced T1-weighted images (Fig. 6D). Biopsy of the prostate revealed adenocarcinoma with Gleason score of 9 ($4 + 5$) that was diagnosed as prostate carcinoma (pT2N1M1) (Fig. 7B). His prostate-specific antigen (PSA) level at time of diagnosis was elevated at 123.9 ng/mL. Bilateral orchiectomy and adjuvant hormonal therapy were performed. He died 47 months after diagnosis of left supraclavicular lymph node metastasis.

Discussion
Metastasis from an infradiaphragmatic tumor to the left supraclavicular lymph node occurs via the rich lymphatic network of the retroperitoneal lymph nodes, cisterna chyli, and the thoracic duct, which drains into the systemic circulation via the left subclavian vein. Infradiaphragmatic tumor metastases to the lymph nodes of the head and neck without lung involvement are considered to occur via the vertebral venous plexus system [9].

Morphologically, the vertebral venous plexus system shows interindividual variability with little or no valves and many branches [10]. Therefore, tumor nests
encounter little resistance as they ascend through the vertebral venous plexus when the intraabdominal or intrathoracic pressure is increased [10], and these tumor nests do not pass through the lung [11].

**Diagnosis**

Combined radiological and serological assessments are useful for the diagnosis of primary cancer. CA19-9 and alpha-fetoprotein levels helped make the diagnosis in our

---

**Fig. 6** 18F-FDG PET/CT and MRI findings. A 18F-FDG PET/CT of the cervical lesion. 18F-FDG uptake was observed in the left supraclavicular lymph node (red arrow). B 18F-FDG PET/CT of the pelvic lesion (green arrow). Strong accumulation of 18F-FDG in the right obturator lymph node was detected. C 18F-FDG PET/CT of the pelvic lesion (green arrow). Weak 18F-FDG uptake was observed in the prostate (green arrow). D A contrast-enhanced MRI scan of the pelvis (fat-saturated contrast-enhanced T1-weighted image). An enhanced lesion was seen in the prostate (red arrow).

**Fig. 7** Pathological image of H–E staining. A Pathological image of the left supraclavicular lymph node (×200). Cribriform glands were recognized. The diagnosis was adenocarcinoma. B Pathological image of the prostate lesion (×200). Mixed solid sheet-like growth and cribriform glands were observed. The diagnosis was adenocarcinoma of the prostate lesion.
first case, as did the PSA level in the second case. $^{18}$F-FDG-PET/CT has greatly improved our ability to detect an unknown primary tumor, particularly at a distant location. However, $^{18}$F-FDG PET/CT sometimes fails to reveal organ-localized prostate cancer [12–15]. In our third case, the $^{18}$F-FDG uptake was weak on $^{18}$F-FDG-PET/CT and MRI findings aided the diagnosis. Thus, prostate cancer cannot be ruled out even if the uptake is weak, and careful examinations, such as PSA measurements, should be considered.

Pathology
In our second case, because of the presence of atypical cells with slight squamous differentiation in the fine-needle aspiration biopsy and the lymph node specimen, the difficulty of obtaining a definitive pathological diagnosis from excisional biopsy of the left supraclavicular lymph node, and the patient's history of squamous cell carcinoma of the tongue, primary cancer screening was started in the head and neck and lung regions. However, the lymph node metastasis originated from the bladder. The histological presentation of urothelial carcinoma is very similar to that of squamous cell carcinoma [11, 16, 17]. If histopathological examination reveals squamous differentiation in metastatic cervical lymph nodes, it is necessary to include the bladder in the search for the primary cancer site [16, 18]. In this case, GATA3(+) staining of the metastasis to the supraclavicular lymph node revealed that the primary cancer was not squamous cell carcinoma of the tongue but urothelial carcinoma in the bladder. The CK7(+) and CK20(−) phenotypes indicate a high probability of bladder urothelial carcinoma [19]. Combined immunolabeling for CK7 and CK20 often aids in the identification of urothelial bladder cancer; however, these markers have limited sensitivity and specificity [19]. Immunohistochemistry of the transcription factor GATA3, a sensitive and specific diagnostic urinary epithelial marker, has been widely used in the diagnosis of urothelial cancer [19, 20].

Prognosis
Our first patient opted for palliative care only and survived for 11 months after diagnosis of lymph node metastasis. There have been some reports of improved survival (for more than 6 years) after successful chemotherapy treatment for metastasis of cholangiocarcinoma to Virchow’s node [21, 22]. Therefore, the prognosis of patients with intrahepatic cholangiocarcinoma and metastasis to the left supraclavicular lymph node is not always poor [21].

The prognosis has been consistently poor in the limited number of case reports on cervical lymph node metastasis from bladder carcinoma [23, 24]. The median survival of patients with metastatic bladder cancer who receive supportive care alone is 4–6 months [18]. Our second patient, who chose palliative care, survived for only 2 months after diagnosis of left supraclavicular lymph node metastasis. As in previous reports, his prognosis was poor.

Even for patients with advanced-stage prostate adenocarcinoma and metastasis to the head and neck region, survival may be extended by rapid diagnosis and appropriate treatment [25]. Hormonal therapy has been shown to prolong survival, even for patients with metastasis of prostate adenocarcinoma to Virchow’s node [26]. One study found that the average survival time was 25.8 (range 1–101) months for patients with prostate adenocarcinoma and Virchow’s node metastasis and pointed out that the prognosis of these patients was superior to that of patients with metastatic adenocarcinoma of non-prostatic origin [25]. Our third patient survived for 47 months after diagnosis of left supraclavicular lymph node metastasis.

The prognosis of malignant infradiaphragmatic tumors after metastasis to Virchow’s node is generally considered to be extremely poor [21]. However, our experience suggests that the prognosis may depend on the characteristics of the tumor and that rapid diagnosis is important for providing appropriate treatment. Enlarged left supraclavicular lymph nodes can be more easily palpated and visually inspected than nodes in other areas of the body. If enlarged left supraclavicular lymph nodes are detected on routine clinical examination, clinicians should request additional assessments such as CT, MRI, ultrasonography, and PET/CT to ensure rapid detection and diagnosis of the primary lesion. In addition, biopsy of the enlarged cervical lymph nodes and serological assessments should be conducted to diagnose the primary cancer.

Further accumulation of cases and more detailed studies of malignant infradiaphragmatic tumors with Virchow’s node metastasis are needed.

Conclusion
We encountered three patients with malignant infradiaphragmatic tumors in whom the initial diagnosis was left supraclavicular lymph node metastasis. Pathological diagnosis and specific diagnosis methods such as radiological and serological assessments are important for providing rapid diagnosis and appropriate treatment. Survival time varied according to the characteristics of the specific tumor type.

Abbreviations
CA19-9: Carbohydrate antigen 19-9; CT: Computed tomography; PSA: Prostate-specific antigen; $^{18}$F-FDG PET/CT: $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography.
Acknowledgements
The authors would like to thank the nurses and other medical staff who assisted in this study.

Authors’ contributions
YM conceived the study, carried out the design and coordination, and wrote the manuscript. YM, MT, and JO collected the clinical data. TK, TK, HH, and HT helped to write the manuscript. HH, TI, and TA supervised this clinical study and helped to write the manuscript. All authors provided feedback on revisions to the manuscript. All authors read and approved the final manuscript.

Funding
This research received no specific grants from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study protocol was approved by the Medical Research Ethics Committee of Tokyo Medical and Dental University (D2015-600; previously 1235). All patients in this manuscript were deidentified. The study was conducted in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Declaration of Helsinki. Written informed consent was obtained from all patients in this study.

Consent for publication
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare no conflicts of interest.

Author details
1Department of Oral and Maxillofacial Surgery, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan. 2Department of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan. 3Department of Nuclear Medicine, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan. 4Division of Diagnostic Radiology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

Received: 20 October 2021 Accepted: 6 January 2022
Published online: 26 January 2022

References
1. Berge T, Toremalm NG. Cervical and mediastinal lymph node metastases as an orhtorhinolaryngic problem. Ann Otol Rhinol Laryngol. 1969;78:663–70.
2. Fernández Aceñero MJ, Caso Vesca A, Díaz Del Arco C. Role of fine needle aspiration cytology in the management of supraclavicular lymph node metastasis: review of our experience. Diagn Cytopathol. 2019;47:181–6.
3. Mroueh R, Nevala A, Haapaniemi A, Pitkäniemi J, Salo T, Mäkitie AA. Risk of second primary cancer in oral squamous cell carcinoma. Head Neck. 2020;42:1848–58.
4. Min SK, Choi SW, Lim J, Park JY, Jung KW, Won WJ. Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry. Oral Oncol. 2019;95:16–28.
5. Hasson H, Strauss M, Sharkey FE. Urogenital tract carcinoma metastatic to the head and neck. Laryngoscope. 1986;96:1352–6.
6. Hemaatpour K, Bennett CJ, Rogers D, Head CS. Supraclavicular lymph node: incidence of unsuspected metastatic prostate cancer. Eur Arch Otorhinolaryngol. 2006;263:872–4.
7. Mueller TJ, Wu H, Greenberg RE, Hudes G, Topham N, Lessin SR, et al. Cutaneous metastases from genitourinary malignancies. Urology. 2004;63:1021–6.
8. Çulpan M, Yıldırım A, Tutan T, Çağkırlı T. Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer. Turk J Urol. 2018;44:75–8.
9. Oh D, Ahn YC, Park HC, Lim DH, Noh JM, Cho WK, et al. The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy. Oncotarget. 2017;8:35700–6.
10. Groen RJ, Groenewegen HJ, van Alphen HA, Hoogland PV. Morphology of the human internal vertebral venous plexus: a cadaver study after intravenous Araldite CY 221 injection. Anat Rec. 1997;249:285–94.
11. López F, Rodrigo JP, Silver CE, Haigentz M Jr, Bishop JA, Strojan P, et al. Cervical lymph node metastases from remote primary tumor sites. Head Neck. 2016;38(Suppl 1):E3274–85.
12. Liu LL, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108–11.
13. Ueda M, Oshihara R, Ishizaki S, Mimaki S. A prostate cancer: only complaint is left neck mass—a case report. Toukekibun. 2014;40:502–6.
14. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–22.
15. Tsujino K, Sasaeda S, Kawahara K, Terada H, Komori C, Suzuki H, et al. A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy. Nihon Kokyuki Gakkai Zassi. 2007;45:648–53.
16. Miettinnen M, McCabe PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13–22.
17. Guver AM, Amin MB, Luthringer DJ, Westfall D, Arora K, Farver CF, et al. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012;136:1339–46.
18. Parimoo D, Raghavan D. Progress in the management of metastatic bladder cancer. Cancer Control. 2000;7:347–56.
19. Wang L, Song G, Zhang W, Zhang Z. The clinicopathological features of metastatic tumors of the bladder: analysis of 25 cases. Int J Clin Exp Pathol. 2018;11:5581–91.
20. Inoue S, Mizushima T, Fujita K, Meliti A, Ide H, Yamaguchi S, et al. GATA3: a multi-specific marker and a prognosticator. Hum Pathol. 2017;64:83–90.
21. Ochiai T, Ikoma H, Inoue K, Komatsu S, Mureyama Y, Shiozaki A, et al. Long-term survival of a patient with common bile duct cancer after Vichow’s node recurrence: report of a case. Surg Today. 2011;41:1432–5.
22. Asakura H, Ohtsuuka M, Ito H, Kimura F, Ambru S, Shinami H, et al. Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology. 2005;52:722–4.
23. Ferlito A, Shaha AR, Buckley JG, Caruso G, Rinaldo A. Metastatic cervical lymph node from urogenital tract carcinoma: a diagnostic and therapeutic challenge. Acta Otolaryngol. 2001;121:556–64.
24. Murahit AT, Mustahhab A, Yasar B, Shoab A, Mohsin F. Cervical lymph node metastasis from transitional cell carcinoma of the urinary tract as a urothelial marker and a prognosticator. Hum Pathol. 2017;64:83–90.
25. Mochizuki et al. Journal of Medical Case Reports (2022) 16:33